GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 billion, betting that growing sales of its HIV and cancer drugs will make ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

GSK has claimed its second breakthrough designation from the FDA for antibody-drug conjugate GSK5764227, which it licensed from China's Hansoh Pharma in a $1.7 billion deal. The status has been ...

Last week's rumour that GSK was poised to make a bid to acquire IDRx and its experimental targeted therapy for a rare form of rare gastrointestinal cancer was on the money. This morning ...

Teva Pharmaceutical Industries Ltd. ADR-0.62% $20.28B ...

With the FDA quietly rolling back DEI initiatives under Trump’s latest executive order, experts warn that underrepresentation ...

After hours: February 3 at 6:25:46 p.m. EST ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.